Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

A novel anti-virulence gene revealed by proteomic analysis in Shigella flexneri 2a.

Proteome science·2010
Same author

Delivery of siRNA therapeutics: barriers and carriers.

The AAPS journal·2010
Same author

Effect of Xuefu Zhuyu Capsule (血府逐瘀胶囊) on the symptoms and signs and health-related quality of life in the unstable angina patients with blood-stasis syndrome after percutaneous coronary intervention: A Randomized controlled trial.

Chinese journal of integrative medicine·2010
Same author

Prognostic factors and outcome of 438 Chinese patients with hepatocellular carcinoma underwent partial hepatectomy in a single center.

World journal of surgery·2010
Same author

Proteomic analysis of hydrogen photoproduction in sulfur-deprived Chlamydomonas cells.

Journal of proteome research·2010
Same author

MSU-S mesoporous materials: an efficient catalyst for isomerization of alpha-pinene.

Bioresource technology·2010

相关实验视频

Updated: Jan 6, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.9K

在先进的非状非小细胞肺癌中进行第一线tislelizumab加化疗:PD-L1 ≥50%从RATIONALE-304试验中的子组分析.

Shun Lu1, Jie Wang2, Yan Yu3

  • 1Department of Oncology, School of Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Xuhui District, 241 Huaihai West Road, Shanghai, 200020, China. shun_lu@hotmail.com.

Oncology and therapy
|September 14, 2025
PubMed
概括

第一线tislelizumab加化疗显著改善了晚期非状非小细胞肺癌 (nsq-NSCLC) 患者的无进展生存期 (PFS) 和整体生存期 (OS),这些患者的PD-L1表达高 (≥50%). 在PD-L1亚组中,疗效一致.

关键词:
反PD-1 抗体的抗体.第一个行第一行.非小细胞肺癌是非小细胞肺癌.第三阶段IIIB-IV阶段这就是Tislelizumab.

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.9K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.0K

相关实验视频

Last Updated: Jan 6, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.9K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.9K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.0K

科学领域:

  • 在瘤学瘤学.
  • 免疫治疗是一种免疫疗法.
  • 临床试验 临床试验

背景情况:

  • 该RATIONALE-304试验研究了第一线tislelizumab加化疗与晚期非状非小细胞肺癌 (nsq-NSCLC) 的化疗.
  • 这项分析专门研究了瘤细胞编程死亡配体1 (PD-L1) 表达率≥50%的患者的结局.

研究的目的:

  • 评估第一线tislelizumab加化疗在晚期nsq-NSCLC患者高PD-L1表达 (≥50%) 的疗效和安全性.
  • 在这个患者亚组中评估无进展生存 (PFS) 和整体生存 (OS).

主要方法:

  • 患有IIIB/IV期nsq-NSCLC的患者被随机分配给接受tislelizumab加化疗和pemetrexed,或化疗和pemetrexed.
  • 主要终点是独立审查委员会 (IRC) 评估的PFS;次要终点包括OS,客观反应率和安全.

主要成果:

  • 在PD-L1≥50%的人群中 (n=110),Tiselelizumab加化疗的PFS中位数为17.2个月,单独使用化疗为4.6个月 (HR 0.29).
  • 平均生存期分别为41.9个月和13.1个月 (HR 0.38).
  • 在PD-L1表达子组 (50-89%和≥90%) 中,疗效一致,安全性概况可控.

结论:

  • 第一线tislelizumab加化学疗法在晚期nsq-NSCLC患者的PFS和OS中提供了临床上有意义的改善,PD-L1表达≥50%.
  • 该治疗在高PD-L1表达水平上表现出一致的疗效.